



11-02-07

cofc

Express Mail No.: EB 132 603 022 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patentee: Young *et al.*

Application No. 09/724,531

Patent No.: 7,229,619

Filed: November 28, 2000

Issued: June 12, 2007

Group Art Unit: 1648

Examiner: Stacy Brown CHEN

For: METHODS OF ADMINISTERING/
DOSING ANTI-RSV ANTIBODIES FOR
PROPHYLAXIS AND TREATMENT

Attorney Docket No: 10271-021-999
(CAM: 209073-999020)

TRANSMITTAL LETTER

Certificate

NOV 06 2007

of Correction

ATTN: Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed herewith for appropriate action by the United States Patent and Trademark Office are the following documents:

1. Request for Expedited Issuance of a Certificate of Correction;
2. Certificate of Correction;
3. Appendix A: Copy of Request for Continued Examination and Amendment dated 11/21/06;
4. Appendix B: Copy of Substitute Sequence Listing dated 11/21/06;
5. Appendix C: Copy of Returned Receipt Post Card stamped by USPTO on 11/21/06;
6. Appendix D: Copy of Notice of Allowability mailed 1/30/07; and
7. Return Post Card.

NOV 6 2007

6 2007

U.S. Patent No. 7,229,619
Request for Certificate of Correction
dated October 31, 2007
Page 2 of 2

This expedited Request for a Certificate of Correction is being submitted to correct errors incurred through the fault of the USPTO. Accordingly, no fees are believed due. However, the Commissioner is authorized to charge any fees necessary or credit any overpayment to Jones Day Deposit Account No. 50-3013.

Date: Oct. 31, 2007

Tamera M. Weisser
For: Anthony M. Insogna
Tamera M. Weisser, Ph.D. (Reg. No. 47,856)

For: Anthony M. Insogna (Reg. No. 35,203)
JONES DAY
222 East 41st Street
New York, NY 10017-6702
(858) 314-1200

NOV 6 2007
2007



Express Mail No.: EB 132 603 022 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patentee: Young *et al.*

Application No. 09/724,531

Patent No.: 7,229,619

Filed: November 28, 2000

Issued: June 12, 2007

Group Art Unit: 1648

Examiner: Stacy Brown CHEN

For: METHODS OF ADMINISTERING/
DOSING ANTI-RSV ANTIBODIES FOR
PROPHYLAXIS AND TREATMENT

Attorney Docket No: 10271-021-999
(CAM: 209073-999020)

REQUEST FOR EXPEDITED ISSUANCE OF CERTIFICATE OF CORRECTION

ATTN: Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. § 1.322, Patentee hereby requests the expedited issuance of a Certificate of Correction in connection with the above-identified patent. The Certificate of Correction setting forth the necessary corrections is submitted concurrently herewith.

Pursuant to MPEP § 1480.01, expedited issuance of a Certificate of Correction can be requested when: (1) the correction requested was incurred through the fault of the USPTO, (2) the matter is clearly disclosed in the records of the USPTO, and (3) the request is accompanied by documentation that unequivocally supports the Patentee's assertion (e.g., copies of postcard receipts, correspondence dated and received by the office, and an Examiner's response indicating entry of the amendments).

Patentee submits that each of the errors corrected herein were incurred through the fault of the USPTO, as unequivocally evidenced by the following documents submitted herewith: copy of the Amendment filed November 21, 2006 (Appendix A); copy of the Substitute Sequence Listing filed November 21, 2006 (Appendix B); copy of the return receipt postcard indicating that the submissions were received by the USPTO on November 21, 2006 (Appendix C); and a copy of the Notice of Allowability mailed January 30, 2007, which indicates, *inter alia*, that the "Applicant's submission filed on November 21, 2006 has been entered" (page 2) (Appendix D).

NOV 6 2007

Table 8 (Col. 91) is being corrected to replace "A4B4" with "A4B4(1) (sequence not shown)," as presented on pages 15-16 and 27 of the November 21, 2006 Amendment. SEQ ID NOS: 33, 44, 46, 68, 75, and 111 of the Sequence Listing are being corrected and SEQ ID NO: 205 and SEQ ID NO: 206 are being added, as presented on pages 17 and 28 of the November 21, 2006 Amendment and Substitute Sequence Listing. An error in claim 64 is also being corrected, as presented on page 25 (Claim 308) of the November 21, 2006 Amendment.

Because each correction herein was previously submitted in the Amendment and Substitute Sequence Listing filed November 21, 2006 (see Appendices A-B), received by the USPTO (see Appendix C), and entered by the Examiner (see Appendix D), Patentee submits that the requirements for expedited issuance of a Certificate of Correction have been met.

No fees are believed to be due for this request. However, if any fees are due, please charge them to Jones Day Deposit Account No. 50-3013.

Date: Oct. 31, 2007



For: 

Tamera M. Weisser, Ph.D. (Reg. No. 47,856)

For: Anthony M. Insogna (Reg. No. 35,203)
JONES DAY
222 East 41st Street
New York, NY 10017-6702
(858) 314-1200

NOV 6 2007

UNITED STATES PATENT AND TRADEMARK OFFICE **CERTIFICATE OF CORRECTION**

PATENT NO. : 7,229,619
 DATED : June 12, 2007
 INVENTOR(S) : James F. Young
 Scott Koenig
 Leslie S. Johnson
 William D. Huse
 Jeffrey D. Watkins
 Herren Wu

Page 1 of 3

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Col. 91, line 45 (in Table 8), change "A4B4" to --A4B4(1) (sequence not shown)--.

Col. 91, line 54 (in Table 8), change "A4B4" to --A4B4(1) (sequence not shown)--.

Col. 111, SEQ ID NO: 33, (amino acid 32), line 2, change "Pro" to --Ala--.

Col. 117, SEQ ID NO: 44, (amino acid 57), line 4, change "Gly" to --Asp--.

Col. 119, SEQ ID NO: 46, (amino acid 24), line 2, change "Ser" to --Leu--.

Col. 131, SEQ ID NO: 68, (amino acids 25-28), line 2, change "Ala Ser Ser Ser" to
 --Pro Ser Ser Arg--.

Col. 131, SEQ ID NO: 68, (amino acid 54), line 4, change "Ala" to --Ser--.

Col. 135, SEQ ID NO: 75, (amino acids 51-52), line 4, change "Phe Phe" to --Leu Leu--.

Col. 145, SEQ ID NO: 111, (amino acid 4), line 1, change "Leu" to --Ser--.

NOV 6 2007

MAILING ADDRESS OF SENDER:
 JONES DAY
 222 East 41st Street
 New York, New York 10017
 (212) 326-3939

PATENT NO. 7,229,619
 No. of add'l. copies
 @ 30¢ per page

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 2 of 3

Col. 171, after SEQ ID NO: 204, insert SEQ ID NO: 205 and SEQ ID NO: 206:

<210> 205
<211> 106
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> VL Domain

<400> 205
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Gly Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
35 40 45
Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Gly Tyr Pro Phe Thr
85 90 95
Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105

NOV 6 2007

MAILING ADDRESS OF SENDER:
JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939

PATENT NO.

7,229,619

No. of add'l. copies
@ 30¢ per page

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

<210> 206
 <211> 120
 <212> PRT
 <213> Homo sapiens

Page 3 of 3

<220>
 <221> misc_feature
 <223> VH Domain

<400> 206
 Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
 1 5 10 15
 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
 20 25 30
 Gly Met Ser Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
 35 40 45
 Trp Leu Ala Asp Ile Trp Trp Asp Asp Lys Lys Asp Tyr Asn Pro Ser
 50 55 60
 Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
 65 70 75 80
 Val Leu Lys Val Thr Asn Met Asp Pro Ala Asp Thr Ala Thr Tyr Tyr
 85 90 95
 Cys Ala Arg Ser Met Ile Thr Asn Trp Tyr Phe Asp Val Trp Gly Gln
 100 105 110
 Gly Thr Thr Val Thr Val Ser Ser
 115 120

Col. 176, lines 2-3 (Claim 64), change "a VL CDR1 or a VL CDR2 of the antibody P12F2" to
 --SEQ ID NO:21 or SEQ ID NO:22--.

NOV 6 2007

MAILING ADDRESS OF SENDER:
 JONES DAY
 222 East 41st Street
 New York, New York 10017
 (212) 326-3939

PATENT NO.

7,229,619

No. of add'l. copies
 @ 30¢ perpage
 LAI-2901922v1

APPENDIX A:

**REQUEST FOR CONTINUED
EXAMINATION AND AMENDMENT
DATED NOVEMBER 21, 2006**

NOV 6 2007



EXPRESS MAIL NO. EQ 238 068 436 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Young <i>et al.</i>	Confirmation No.:	7010
Serial No.:	09/724,531	Art Unit:	1648
Filed:	November 28, 2000	Examiner:	Stacy Brown Chen
For:	METHODS OF ADMINISTERING/DOSING ANTI-RSV ANTIBODIES FOR PROPHYLAXIS AND TREATMENT	Attorney Docket No:	10271-021-999
		(CAM No.	209073-999020)

REQUEST FOR CONTINUED EXAMINATION AND AMENDMENT

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In lieu of Issue Fee payment for the above-referenced patent application, which is due on or before November 22, 2006, Applicants are submitting herewith a Request for Continued Examination (RCE) and Amendment. Applicants respectfully request that the following amendments and remarks be entered into the record and considered by the Examiner. Applicants submit herewith: (a) a Request for Continued Examination (RCE), with provisions for the required fee; (b) a Substitute Sequence Listing (one paper copy and one Computer Readable Form (CRF) copy on compact disc); (c) a Supplemental Information Disclosure Statement; and (d) a List of References Cited by Applicant

Please amend the above-referenced application as follows.

Amendments to the Specification begin on page 2 of this document.

Amendments to the Claims are reflected in the listing of claims which begins on page 18 of this document.

Remarks begin on page 27 of this document.

NOV 6 2007

AMENDMENTS TO THE SPECIFICATION:

- **On page 32, please replace the paragraph spanning lines 19-22 with the following paragraph:**

Figures 2A-2B show the (A) light chain variable region (SEQ ID NO:205) and (B) heavy light chain variable region for an antibody sequence (SEQ ID NO:206). CDR regions are underlined. This sequence differs from the sequence disclosed in Figures 1A-1B in the first 4 residues of VH CDR1 of the light chain, residue 103 of the light chain and residue 112 of the heavy chain.

- **On page 51, please replace Table 3 with the following Table 3:**

Table 3. CDR Sequences

VH CDR1	VH CDR2	VH CDR3	VL CDR1	VL CDR2	VL CDR3
TSGMSVG (SEQ ID NO:1)	DIWWD DKKHY NPSLK S (SEQ ID NO:2)	S MITN WY FDV (SEQ ID NO:3)	K COLSVGYMH (SEQ ID NO:4)	DTSK L AS (SEQ ID NO:5)	FQSGYPFT (SEQ ID NO:6)
TPGMSVG (SEQ ID NO:17)	DIWWD DKKHY NPSLK D (SEQ ID NO:18)	D MITN WY FDV (SEQ ID NO:76)	K COSSVGYMH (SEQ ID NO:77)	DTSY L AS (SEQ ID NO:78)	
TAGMSVG (SEQ ID NO:10)	DIWWD DKKHY NPSLK S (SEQ ID NO:79)	D MITN WY FDV (SEQ ID NO:80)	K CO S R V GYMH (SEQ ID NO:81)	DTSY L SS (SEQ ID NO:82)	
	DIWWD DKKHY NPSLK D (SEQ ID NO:83)	D MIEN WY FDV (SEQ ID NO:29)	K COLRVGYMH (SEQ ID NO:84)	DTKK L SS (SEQ ID NO:85)	
	DIWWD DKKHY NPSLK D (SEQ ID NO:18)	D MIEN WY FDV (SEQ ID NO:19)	K L O LSVGYMH (SEQ ID NO:86)	DTFY L SS (SEQ ID NO:49)	
	DIWWD DKKHY NPSLK S (SEQ ID NO:87)	S MITN WY FDV (SEQ ID NO:11)	K LO S SVGYMH (SEQ ID NO:88)	DTFK L AS (SEQ ID NO:14)	
	DIWWD DKKHY NPSLK D (SEQ ID NO:89)	S MIEN WY FDV (SEQ ID NO:90)	K LO S RVGYMH (SEQ ID NO:91)	DTFK L SS (SEQ ID NO:35)	
	DIWWD GKKHY NPSLK D (SEQ ID NO:24)	S MIEN WY FDV (SEQ ID NO:92)	K L O L R VGYMH (SEQ ID NO:93)	DTFY L AS (SEQ ID NO:94)	

	DIWWDGKK D YNPSLK S (SEQ ID NO:95) (SEQ ID NO:96)		<u>KLSLS</u> VG Y M H (SEQ ID NO:96) (SEQ ID NO:97)	DTSKLP S (SEQ ID NO:97) (SEQ ID NO:98)	
	DIWWDGKK D YNPSLK D (SEQ ID NO:37)		<u>KLSSS</u> VG Y M H (SEQ ID NO:98) (SEQ ID NO:99)	DTSG L A S (SEQ ID NO:99) (SEQ ID NO:100)	
	DIWWDGKK H YNPSLK S (SEQ ID NO:95)		<u>KLSSR</u> VG Y M H (SEQ ID NO:101)	DTSG L P S (SEQ ID NO:102)	
	DIWWD D KK S YNPSLK S (SEQ ID NO:103)		<u>KLSLR</u> VG Y M H (SEQ ID NO:104)	DTRG L P S (SEQ ID NO:27)	
	DIWWD D KK S YNPSLK D (SEQ ID NO:105)		<u>KCSLS</u> VG Y M H (SEQ ID NO:106)	DTRK L A S (SEQ ID NO:107)	
	DIWWD G KK S YNPSLK S (SEQ ID NO:108)		<u>KCSSS</u> VG Y M H (SEQ ID NO:109)	DTRG L A S (SEQ ID NO:110)	
	DIWWDGKK S YNPSLK D (SEQ ID NO:41)		<u>KCSSR</u> VG Y M H (SEQ ID NO:111)	DTRK L P S (SEQ ID NO:112)	
			<u>KCSLR</u> VG Y M H	DTMR L A S	

			(SEQ ID NO:113)	(SEQ ID NO:32)	
			<u>SLSL</u> SVGYMH (SEQ ID NO:114)	DT <u>MK</u> LAS (SEQ ID NO:115)	
			<u>SLSS</u> SVGYMH (SEQ ID NO:116)	DT <u>SRL</u> AS (SEQ ID NO:117)	
			<u>SLSSR</u> VGMYH (SEQ ID NO:21)	DT <u>SLL</u> AS (SEQ ID NO:118)	
			<u>SLSLR</u> VGMYH (SEQ ID NO:119)	DT <u>SLL</u> DS (SEQ ID NO:120)	
			<u>SCOLS</u> VGMYH (SEQ ID NO:121)	DT <u>SKL</u> DS (SEQ ID NO:122)	
			<u>SCOSS</u> VGMYH (SEQ ID NO:123)	DT <u>L</u> LDS (SEQ ID NO:124)	
			<u>SCOSR</u> VGMYH (SEQ ID NO:125)	DT <u>LKL</u> DS (SEQ ID NO:126)	
			<u>SCOLR</u> VGMYH (SEQ ID NO:127)	DT <u>L</u> LAS (SEQ ID NO:128)	

			<u>SLOLSVGYMH</u> (SEQ ID NO:129)	<u>DTLKLAS</u> (SEQ ID NO:130)	
			<u>SLOSSVGYMH</u> (SEQ ID NO:131)	<u>DTSKLSS</u> (SEQ ID NO:132)	
			<u>SLOS RVGYMH</u> (SEQ ID NO:133)	<u>DTSKOAS</u> (SEQ ID NO:134)	
			<u>SLOLRVGYMH</u> (SEQ ID NO:135)	<u>DTSKOSS</u> (SEQ ID NO:136)	
			<u>SCSLSVGYMH</u> (SEQ ID NO:137)	<u>DTSYLAS</u> (SEQ ID NO:138)	
			<u>SCSSSVGYMH</u> (SEQ ID NO:139)	<u>DTSYLSS</u> (SEQ ID NO:140)	
			<u>SCSSRVGYMH</u> (SEQ ID NO:141)	<u>DTSYQAS</u> (SEQ ID NO:142) (SEQ ID NO:143)	
			<u>SCSLRVGYMH</u> (SEQ ID NO:143)	<u>DTSYQSS</u> (SEQ ID NO:144)	

			(SEQ ID NO:144)	(SEQ ID NO:142)	
			<u>KPSSRVGYMH</u> (SEQ ID NO:145)	<u>DTMYQAS</u> (SEQ ID NO:146)	
			<u>KPSLRVGYMH</u> (SEQ ID NO:147)	<u>DTMYQSS</u> (SEQ ID NO:43)	
			<u>KPSSSVGYMH</u> (SEQ ID NO:148)	<u>DTMKOAS</u> (SEQ ID NO:149)	
			<u>KPSLSVGYMH</u> (SEQ ID NO:150)	<u>DTMKOSS</u> (SEQ ID NO:151)	
			<u>KPOSRVGYMH</u> (SEQ ID NO:152)	<u>DTMYLAS</u> (SEQ ID NO:153)	
			<u>KPOLRVGYMH</u> (SEQ ID NO:154)	<u>DTMYLSS</u> (SEQ ID NO:155)	
			<u>KPOSSVGYMH</u> (SEQ ID NO:156)	<u>DTMKLAS</u> (SEQ ID NO:157)	
			<u>KPOLSVGYMH</u> (SEQ ID NO:158)	<u>DTMKLSS</u> (SEQ ID NO:159)	

			<u>SPSSRVGYMH</u> (SEQ ID NO:160)	<u>DTSKLSS</u> (SEQ ID NO:161)	
			<u>SPSLRVGYMH</u> (SEQ ID NO:162)	<u>DTRYQAS</u> (SEQ ID NO:163)	
			<u>SPSSSVGYMH</u> (SEQ ID NO:164)	<u>DTRYQSS</u> (SEQ ID NO:164)	
			<u>SPSLSVGYMH</u> (SEQ ID NO:165)	<u>DTRKQAS</u> (SEQ ID NO:166)	
			<u>SPOSRVGYMH</u> (SEQ ID NO:167)	<u>DTRKQSS</u> (SEQ ID NO:168)	
			<u>SPQLRVGYMH</u> (SEQ ID NO:169)	<u>DTRKLAS</u> (SEQ ID NO:170)	
			<u>SPOSSVGYMH</u> (SEQ ID NO:171)	<u>DTRKLSS</u> (SEQ ID NO:172)	
			<u>SPOLSVGYMH</u> (SEQ ID NO:173)	<u>DTRYLAS</u> (SEQ ID NO:174)	
			<u>KAOSRVGYMH</u> (SEQ ID NO:175)	<u>DTRYLSS</u> (SEQ ID NO:177)	

			<u>KAQLRVGYMH</u> (SEQ ID NO:176)			
			<u>KAQSSVGYMH</u> (SEQ ID NO:178)			
			<u>KAQLSVGYMH</u> (SEQ ID NO:179)			
			<u>KASSRVGYMH</u> (SEQ ID NO:180)			
			<u>KASLRVGYMH</u> (SEQ ID NO:181)			
			<u>KASSSVGYMH</u> (SEQ ID NO:182)			
			<u>KASLSVGYMH</u> (SEQ ID NO:183)			
			<u>SASSRVGYMH</u> (SEQ ID NO:39)			
			<u>SASLRVGYMH</u> (SEQ ID NO:184)			

			<u>SASSSVGYMH</u> (SEQ ID NO:13)			
			<u>SASLSVGYMH</u> (SEQ ID NO:185)			
			<u>SAOSRVGYMH</u> (SEQ ID NO:186)			
			<u>SAOLRVGYMH</u> (SEQ ID NO:187)			
			<u>SAQSSVGYMH</u> (SEQ ID NO:188)			
			<u>LPSSRVGYMH</u> (SEQ ID NO:47)			
			<u>LPSLSVGYMH</u> (SEQ ID NO:189)			
			<u>LPSSSVGYMH</u> (SEQ ID NO:190)			
			<u>LPSLRVGYMH</u> (SEQ ID NO:191)			

			<u>LCSSRVGYMH</u> (SEQ ID NO:192)			
			<u>LCSLSVGYMH</u> (SEQ ID NO:193)			
			<u>LCSSSVGYMH</u> (SEQ ID NO:194)			
			<u>LCSLRVGYMH</u> (SEQ ID NO:195)			
			<u>LPQSRVGYMH</u> (SEQ ID NO:196)			
			<u>LPOLSVGYMH</u> (SEQ ID NO:197)			
			<u>LPQSSVGYMH</u> (SEQ ID NO:198)			
			<u>LPOLRVGYMH</u> (SEQ ID NO:199)			
			<u>LCQSRVGYMH</u> (SEQ ID NO:200)			

			<u>LCQLSVGYMH</u> (SEQ ID NO:201)			
			<u>LCQSSVGYMH</u> (SEQ ID NO:202)			
			<u>LCQLRVGYMH</u> (SEQ ID NO:203)			
			<u>SAQLSVGYMH</u> (SEQ ID NO:204)			

- On page 117, please replace Table 5 with the following Table 5:

Table 5.

<u>Monoclonal Antibodies vs Bac-F (1:1)</u>				
	Kon (x E+5)	Koff (x E-5)	KD (nM)	Chi2
P12F2	4.07	12.8	0.31 (13)	0.9
P12F4	4.95	5.55	0.11 (35)	0.6
A13c4	3.00	3.96	0.13 (30)	1.2
A12a6	4.60	1.65	0.04 (98)	1.2
A1e9	4.33	14.3	0.33 (12)	2.5
A8c7	4.17	8.75	0.21 (19)	1.8
P11d4	4.66	28.9	0.62 (6)	1.0
A17d4	4.56	4.07	0.09 (43)	0.5
A4B4(1) (Sequence not shown)	4.34	1.06	0.02 (195)	1.5
SYNAGIS®	1.32	51.5	3.90 (1)	0.6

- On page 118, please replace Table 6 with the following Table 6:

Table 6.

<u>Monoclonal Antibodies vs NUF4 (1:1)</u>				
	Kon (x E+5)	Koff (x E-5)	KD (nM)	Chi2
P12F2	5.41	17.8	0.33 (26)	1.2
P12F4	9.43	22.9	0.24 (36)	0.9
A13c4	3.65	27.2	0.75 (12)	1.8
A12a6	4.00	29.1	0.73 (12)	1.9
A1e9	8.43	58.4	0.69 (13)	0.9

NOV 6 2007

A8c7	8.25	53.5	0.65 (13)	0.7
P11d4	9.04	76.6	0.85 (10)	2.5
A17d4	4.99	36.2	0.73 (12)	2.0
A4B4(1)	4.96	28.2	0.57 (15)	1.9
<u>(Sequence not shown)</u>				
SYNAGIS®	3.04	265	8.70 (1)	0.4

- On page 118, please replace Table 7 with the following Table 7:

Table 7.

<u>Monoclonal Antibodies vs NUF4 (2:1)</u>				
	<u>K_{on} (x E+5)</u>	<u>K_{off} (x E-5)</u>	<u>K_D (nM)</u>	<u>Chi2</u>
P12F2	2.82	23.6	0.84 (371)	1.5
P12F4	2.73	63.6	2.33 (134)	4.9
A13c4	3.20	22.5	0.70 (446)	1.7
A12a6	2.18	40.8	1.87 (167)	1.9
A1e9	3.29	139	4.22 (74)	2.8
A8c7	4.30	114	2.65 (118)	2.0
P11d4	3.66	313	8.55 (36)	3.6
A17d4	2.64	29.2	1.11 (281)	1.7
A4B4(1)	2.03	40.06	2.00 (156)	1.4
<u>(Sequence not shown)</u>				
SYNAGIS®	0.78	2420	312 (1)	1.3

- On pages 118-119, please replace the paragraph spanning page 118, line 35 – page 119, line 7 with the following paragraph:

NOV 6 2007

1X-493L2FR, H3-3F4, M3H9, Y10H6, DG, *AFFF, 6H8, L1-7E5, L2-15B10, *P12F2, *P12F4, *P11d4, *A1e9, *A12a6, *A13a11, and *A13c4 are Fab fragments having the framework sequences of ~~Figure 1~~ Figure 2 and the ~~indicated~~ CDR sequences indicated listed in Table 2. ~~SYNAGIS®, AFFF, P12F2, P12F4, P11d4, A1e9, A12a6, A13c4, A17d4, A4B4 and A8c7 are actual monoclonal antibodies~~ SYNAGIS® is a monoclonal antibody with the framework sequences of Figure 1 and constant regions as described in Johnson et al. (1997, Journal of Infectious Diseases 176:1215-1224) and U.S. Patent No. 5,824,307. The framework sequences of these ~~antibodies~~ this antibody may differ slightly from those of the Fab fragments.

- On pages 120-121, please replace Table 8 with the following Table 8:

Table 8. End Point RSV Microneutralization Titer Of High On Rate Mutant IgG and Fab

Molecule	Mean IC50 (Curve) µg/ml	STDEV Curve IC50	Fold Difference (Curve ICX50)	Mean IC50 (Control) µg/ml	STDEV Control IC50	Fold Difference (Control IC50)	n (assay repeat)
SYNAGIS®	0.4527	0.208	-	0.5351	0.238	-	8
**A1e9	0.0625	0.0268	7	0.0645	0.0223	8	3
**A17d4	0.0342	0.022	13	0.0354	0.0187	15	4
**P11d4	0.0217	0.0331	21	0.0289	0.0110	19	5
**P12F2	0.0231	0.0141	20	0.0223	0.0083	24	6
**A8c7	0.0337	0.0309	13	0.0383	0.0283	14	5
**A12a6	0.0357	0.0316	13	0.0354	0.0261	15	7
**P12F4	0.0242	0.0163	19	0.0235	0.0076	23	7
**A13c4	0.0376	0.0268	12	0.0375	0.0213	14	6
**A4B4(1) (Sequence not shown)	0.0171	0.0018	27	0.0154	0.00417	35	2
*A1e9	0.157	-	3	0.125	-	4	1
*A17d4	0.0179	-	25	0.0171	-	31	1

*P11d4	>1.00	-	-	>1.00	-	-	1
*P12F2	0.0407	0.0112	11	0.0326	0.00905	16	2
*A8c7	0.177	-	3	0.157	-	34	1
*A12a6	0.0287	0.00417	16	0.0310	0.00982	17	2
*P12F4	0.0464	0.00791	10	0.0351	0.0126	15	2
*A13c4	0.0264	0.00141	17	0.0258	0.00071	21	2
*A4B4(1) (Sequence not shown)	0.0414	-	11	0.0411	-	13	1
*A13a11	0.120	0.0222	4	0.1022	0.0260	5	2
*A1h5	0.194	0.462	2	0.176	0.0625	3	2

** Monoclonal Antibody

* Fab Fragment

• On page 122, please replace the paragraph spanning lines 11-18 with the following paragraph:

Antibodies having the amino acid sequence of A13c4, A17d4, A4B4 A4B4(1) (sequence not shown), and SYNAGIS® were diluted in dialysate and the concentrations were determined by UV spectroscopic absorption measurements with a Perkin-Elmer Lambda 4B Spectrophotometer using an extinction coefficient of $217,000 \text{ M}^{-1} \text{ cm}^{-1}$ at the peak maximum at 280 nm. The diluted NUF4 concentrations were calculated from the ratio of the mass of the original sample to that of the diluted sample since its extinction coefficient was too low to determine an accurate concentration without employing and losing a large amount of sample.

• On page 123, please replace the paragraph spanning lines 21 – 34 with the following paragraph.

The ITC results are summarized in Table 9. The higher than 2 stoichiometries in Table 9 indicate that either the concentration determination of the antibody or NUF4 was

incorrect. Since the same NUF4 sample was used as a titrant with antibodies having the amino acid sequence of A13c4 at 35°C and A17d4 at 35°C, which exhibit in at least one of the titrations the correct stoichiometry of 2, it is assumed that the titrant concentration was correct and that the large values of n result from incorrectly determined antibody concentrations. However, it can be shown that the binding constants are critically dependent on the titrant concentration and, thus, despite the 2-3 disparity in n , the binding constants are correct. Since the binding constants of antibodies having the amino acid sequence of A4B4(1) (sequence not shown) and A13c4 at 25°C were near the upper determination limit by ITC (equation 2) and with the limited amount of available NUF4, it was decided to use 35°C as the reference temperature for comprising the binding affinities. The results summarized in Table 9 show that the binding affinities to NUF4 are in the order A4B4(1) > A13c4 > A17d4 > SYNAGIS®.

- On page 123 - 124, please replace Table 9 with the following Table 9:

Table 9. Average Binding Constants and Enthalpies of NUF4 to Antibodies

Antibody	K_b	ΔH_b in kJ mol^{-1}
A4B4(1) (Sequence not shown)	$269 \pm 74 \times 10^6 \text{ M}^{-1}$ or $\sim 3.7 \text{ nM}^*$	92.8 ± 1.0
A13c4	$107 \pm 28 \times 10^6 \text{ M}^{-1}$ or 9 nM	67 ± 17
A17d4	$75 \pm 14 \times 10^6 \text{ M}^{-1}$ or 13 nM	68 ± 10
SYNAGIS®	$1.23 \pm 0.17 \times 10^6 \text{ M}^{-1}$ or 810 nM	71 ± 5

* Based only on the best titration run at 35°C.

4.0 nM is ITC lower limit of $1/K_b$ range (ITC range is limited to $[\text{antibody}]_n K_b = 500$ where n is the stoichiometry and $[\text{antibody}]$ is the concentration of the antibody in the cell).

- Between pages 127 and 128, on a separate page, please replace the Sequence Listing with the Sequence Listing submitted herewith.

NOV 6 2007

AMENDMENT TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing Of The Claims:

1. (Currently Amended) An isolated antibody comprising a variable heavy (VH) domain having a complementarity determining region (CDR) 1 having the amino acid sequence of SEQ ID NO:10, a VH CDR2 having the amino acid sequence of SEQ ID NO:18, a VH CDR3 having the amino acid sequence of SEQ ID NO:19, and framework regions having the amino acid sequence of the VH domain framework regions depicted in Figure 2B (SEQ ID NO:206) having the amino acid sequence of SEQ ID NO:48, wherein said antibody immunospecifically binds to a respiratory syncytial virus (RSV) F protein.
2. (Canceled)
3. (Currently Amended) An isolated antibody comprising a variable light (VL) domain having a CDR1 having the amino acid sequence of SEQ ID NO:21, a VL CDR2 having the amino acid sequence of SEQ ID NO:22, a VL CDR3 having the amino acid sequence of SEQ ID NO:6, and framework regions having the amino acid sequence of the VL domain framework regions depicted in Figure 2A (SEQ ID NO:205) having the amino acid sequence of SEQ ID NO:20, wherein said antibody immunospecifically binds to a RSV F protein.
4. (Canceled)
5. (Currently Amended) The antibody of claim 3 further comprising a VH domain having a CDR1 having the amino acid sequence of SEQ ID NO:10, a VH CDR2 having the amino acid sequence of SEQ ID NO:18, a VH CDR3 having the amino acid sequence of SEQ ID NO:19, and framework regions having the amino acid sequence of the VH domain framework regions depicted in Figure 2B (SEQ ID NO:206) having the amino acid sequence of SEQ ID NO:48.
- 6.-178. (Canceled)

179. (Currently Amended) An isolated antibody comprising a ~~complementarity determining region (CDR)~~ CDR having the amino acid sequence of a ~~VH CDR of the antibody A4B4~~ SEQ ID NO:10, SEQ ID NO:18 or SEQ ID NO:19, wherein said antibody immunospecifically binds to a RSV F protein.
180. (Previously Presented) An isolated antibody comprising a VH CDR1 having the amino acid sequence of SEQ ID NO:10, wherein said antibody immunospecifically binds to a RSV F protein.
181. (Previously Presented) An isolated antibody comprising a VH CDR2 having the amino acid sequence of SEQ ID NO:18, wherein said antibody immunospecifically binds to a RSV F protein.
182. (Previously Presented) An isolated antibody comprising a VH CDR3 having the amino acid sequence of SEQ ID NO:19, wherein said antibody immunospecifically binds to a RSV F protein.
183. (Previously Presented) An isolated antibody comprising a VL CDR1 having the amino acid sequence of SEQ ID NO:21, wherein said antibody immunospecifically binds to a RSV F protein.
184. (Previously Presented) An isolated antibody comprising a VL CDR2 having the amino acid sequence of SEQ ID NO:22, wherein said antibody immunospecifically binds to a RSV F protein.
185. (Canceled)
186. (Previously Presented) The antibody of claim 180, wherein the antibody further comprises a VH CDR2 having the amino acid sequence of SEQ ID NO:18.
187. (Previously Presented) The antibody of claim 180, wherein the antibody further comprises a VH CDR3 having the amino acid sequence of SEQ ID NO:19.
188. (Canceled)
189. (Previously Presented) The antibody of claim 181, wherein the antibody further comprises a VH CDR3 having the amino acid sequence of SEQ ID NO:19.

- 190.-191. (Canceled)
192. (Previously Presented) The antibody of claim 183, wherein the antibody further comprises a VL CDR2 having the amino acid sequence of SEQ ID NO:22.
193. (Previously Presented) The antibody of claim 183, wherein the antibody further comprises a VL CDR3 having the amino acid sequence of SEQ ID NO: 6.
194. (Canceled)
195. (Previously Presented) The antibody of claim 184, wherein the antibody further comprises a VL CDR3 having the amino acid sequence of SEQ ID NO: 6.
- 196.-200. (Canceled)
201. (Previously Presented) The antibody of claim 183, wherein the antibody further comprises a VL CDR2 having the amino acid sequence of SEQ ID NO:22 and a VL CDR3 having the amino acid sequence of SEQ ID NO: 6.
- 202.-203. (Canceled)
204. (Previously Presented) The antibody of claim 180, wherein the antibody further comprises a VL CDR1 having the amino acid sequence of SEQ ID NO:21.
205. (Previously Presented) The antibody of claim 180, wherein the antibody further comprises a VL CDR2 having the amino acid sequence of SEQ ID NO:22.
206. (Previously Presented) The antibody of claim 180, wherein the antibody further comprises a VL CDR3 having the amino acid sequence of SEQ ID NO: 6.
207. (Previously Presented) The antibody of claim 181, wherein the antibody further comprises a VL CDR1 having the amino acid sequence of SEQ ID NO:21.
208. (Previously Presented) The antibody of claim 181, wherein the antibody further comprises a VL CDR2 having the amino acid sequence of SEQ ID NO:22.

NOV 6 2007

209. (Previously Presented) The antibody of claim 181, wherein the antibody further comprises a VL CDR3 having the amino acid sequence of SEQ ID NO: 6.
210. (Previously Presented) The antibody of claim 182, wherein the antibody further comprises a VL CDR1 having the amino acid sequence of SEQ ID NO:21.
211. (Previously Presented) The antibody of claim 182, wherein the antibody further comprises a VL CDR2 having the amino acid sequence of SEQ ID NO:22.
212. (Previously Presented) The antibody of claim 182, wherein the antibody further comprises a VL CDR3 having the amino acid sequence of SEQ ID NO: 6.
- 213.-221. (Canceled)
222. (Previously Presented) The antibody of claim 186, wherein the antibody further comprises a VL CDR1 having the amino acid sequence of SEQ ID NO:21.
223. (Previously Presented) The antibody of claim 186, wherein the antibody further comprises a VL CDR2 having the amino acid sequence of SEQ ID NO:22.
224. (Previously Presented) The antibody of claim 186, wherein the antibody further comprises a VL CDR3 having the amino acid sequence of SEQ ID NO: 6.
225. (Previously Presented) The antibody of claim 187, wherein the antibody further comprises a VL CDR1 having the amino acid sequence of SEQ ID NO:21.
226. (Previously Presented) The antibody of claim 187, wherein the antibody further comprises a VL CDR2 having the amino acid sequence of SEQ ID NO:22.
227. (Previously Presented) The antibody of claim 187, wherein the antibody further comprises a VL CDR3 having the amino acid sequence of SEQ ID NO: 6.

228.-230. (Canceled)

231. (Previously Presented) The antibody of claim 189, wherein the antibody further comprises a VL CDR1 having the amino acid sequence of SEQ ID NO:21.

232. (Previously Presented) The antibody of claim 189, wherein the antibody further comprises a VL CDR2 having the amino acid sequence of SEQ ID NO:22.

233. (Previously Presented) The antibody of claim 189, wherein the antibody further comprises a VL CDR3 having the amino acid sequence of SEQ ID NO: 6.

234-240. (Canceled)

241. (Previously Presented) The antibody of claim 222, wherein the antibody further comprises a VL CDR2 having the amino acid sequence of SEQ ID NO:22.

242. (Previously Presented) The antibody of claim 223, wherein antibody further comprises a VL CDR3 having the amino acid sequence of SEQ ID NO: 6.

243. (Canceled).

244. (Previously Presented) The antibody of claim 225, wherein the antibody further comprises a VL CDR2 having the amino acid sequence of SEQ ID NO:22.

245. (Previously Presented) The antibody of claim 226, wherein antibody further comprises a VL CDR3 having the amino acid sequence of SEQ ID NO: 6.

246-249. (Canceled).

250. (Previously Presented) The antibody of claim 231, wherein the antibody further comprises a VL CDR2 having the amino acid sequence of SEQ ID NO:22.

251-279. (Canceled)

280. (Previously Presented) The antibody of claim 1, 3, 179, 180, 181, 182, 183, or 184, wherein the antibody is a monoclonal antibody.

281. (Previously Presented) The antibody of claim 1, 3, 179, 180, 181, 182, 183, or 184, wherein the antibody is a human antibody.
282. (Previously Presented) The antibody of claim 1, 3, 179, 180, 181, 182, 183, or 184, wherein the antibody is a humanized antibody.
283. (Previously Presented) The antibody of claim 1, 3, 179, 180, 181, 182, 183, or 184, wherein the antibody is a chimeric antibody, single chain Fv, single chain antibody, F(ab')₂ fragment, or Fab fragment.
284. (Previously Presented) The antibody of claim 1, 3, 179, 180, 181, 182, 183, or 184, wherein the antibody is conjugated to a therapeutic or drug moiety.
285. (Previously Presented) The antibody of claim 1, 3, 179, 180, 181, 182, 183, or 184, wherein the antibody is conjugated to a detectable substance.
286. (Previously Presented) A composition comprising the antibody of claim 1, 3, 179, 180, 181, 182, 183, or 184 and a pharmaceutically acceptable carrier or excipient.
287. (Previously Presented) A kit comprising the antibody of claim 1, 3, 179, 180, 181, 182, 183, or 184, in one or more containers, and instructions for use.
288. (Previously Presented) The antibody of claim 192, wherein the antibody further comprises a VH CDR1 having the amino acid sequence of SEQ ID NO:10.
289. (Previously Presented) The antibody of claim 193, wherein the antibody further comprises a VH CDR1 having the amino acid sequence of SEQ ID NO:10.
290. (Previously Presented) The antibody of claim 195, wherein the antibody further comprises a VH CDR1 having the amino acid sequence of SEQ ID NO:10.
291. (Previously Presented) The antibody of claim 201, wherein the antibody further comprises a VH CDR1 having the amino acid sequence of SEQ ID NO:10.
292. (Previously Presented) The antibody of claim 192, wherein the antibody further comprises a VH CDR2 having the amino acid sequence of SEQ ID NO:18.

293. (Previously Presented) The antibody of claim 193, wherein the antibody further comprises a VH CDR2 having the amino acid sequence of SEQ ID NO:18.
294. (Previously Presented) The antibody of claim 195, wherein the antibody further comprises a VH CDR2 having the amino acid sequence of SEQ ID NO:18.
295. (Previously Presented) The antibody of claim 201, wherein the antibody further comprises a VH CDR2 having the amino acid sequence of SEQ ID NO:18.
296. (Previously Presented) The antibody of claim 192, wherein the antibody further comprises a VH CDR3 having the amino acid sequence of SEQ ID NO:19.
297. (Previously Presented) The antibody of claim 193, wherein the antibody further comprises a VH CDR3 having the amino acid sequence of SEQ ID NO:19.
298. (Previously Presented) The antibody of claim 195, wherein the antibody further comprises a VH CDR3 having the amino acid sequence of SEQ ID NO:19.
299. (Previously Presented) The antibody of claim 201, wherein the antibody further comprises a VH CDR3 having the amino acid sequence of SEQ ID NO:19.
- 300.-302. (Canceled)
303. (Previously Presented) The antibody of claim 187, wherein the antibody further comprises a VL CDR1 having the amino acid sequence of SEQ ID NO:21 and a VL CDR3 having the amino acid sequence of SEQ ID NO:6.
304. (Canceled)
305. (Previously Presented) The antibody of claim 187, wherein the antibody further comprises a VL CDR1 having the amino acid sequence of SEQ ID NO:21, a VL CDR2 having the amino acid sequence of SEQ ID NO:22, and a VL CDR3 having the amino acid sequence of SEQ ID NO:6.

NOV 6 2007

306. (Previously Presented) The antibody of claim 189, wherein the antibody further comprises a VL CDR1 having the amino acid sequence of SEQ ID NO:21 and a VL CDR3 having the amino acid sequence of SEQ ID NO:6.
307. (Previously Presented) The antibody of claim 189, wherein the antibody further comprises a VL CDR1 having the amino acid sequence of SEQ ID NO:21, a VL CDR2 having the amino acid sequence of SEQ ID NO:22, and a VL CDR3 having the amino acid sequence of SEQ ID NO:6.
308. (Currently Amended) An isolated antibody comprising a CDR having the amino acid sequence of ~~a VL CDR1 or a VL CDR2 of the antibody P12F2~~ SEQ ID NO:21 or SEQ ID NO:22, wherein said antibody immunospecifically binds to a RSV F protein.
309. (Previously Presented) The antibody of claim 186, wherein the antibody further comprises a VH CDR3 having the amino acid sequence of SEQ ID NO: 19.
310. (Previously Presented) The antibody of claim 309, wherein the antibody further comprises a VL CDR1 having the amino acid sequence of SEQ ID NO: 21.
311. (Previously Presented) The antibody of claim 309, wherein the antibody further comprises a VL CDR2 having the amino acid sequence of SEQ ID NO:22.
312. (Previously Presented) The antibody of claim 309, wherein the antibody further comprises a VL CDR3 having the amino acid sequence of SEQ ID NO:6.
313. (Previously Presented) The antibody of claim 310, wherein the antibody further comprises a VL CDR2 having the amino acid sequence of SEQ ID NO:22.
314. (Previously Presented) The antibody of claim 310, wherein the antibody further comprises a VL CDR3 having the amino acid sequence of SEQ ID NO:6.
315. (Previously Presented) The antibody of claim 311, wherein the antibody further comprises a VL CDR3 having the amino acid sequence of SEQ ID NO:6.

- 316. (Previously Presented) The antibody of claim 313, wherein the antibody further comprises a VL CDR3 having the amino acid sequence of SEQ ID NO:6.
- 317. (Previously Presented) The antibody of claim 222, wherein the antibody further comprises a VL CDR3 having the amino acid sequence of SEQ ID NO:6.
- 318. (Previously Presented) The antibody of claim 241, wherein the antibody further comprises a VL CDR3 having the amino acid sequence of SEQ ID NO:6.
- 319. (Previously Presented) The antibody of claim 232, wherein the antibody comprises a VL CDR3 having the amino acid sequence of SEQ ID NO:6.
- 320. (Previously Presented) The composition of claim 286 formulated for pulmonary, intranasal or parenteral administration.
- 321. (Previously Presented) The composition of claim 286 which is a sustained release formulation.
- 322. (Previously Presented) A lyophilized formulation comprising the antibody of claim 1, 3, 179, 180, 181, 182, 183 or 184.
- 323. (Previously Presented) A liquid formulation comprising the antibody of claim 1, 3, 179, 180, 181, 182, 183 or 184.
- 324. (Previously Presented) A composition comprising the antibody of claim 1, 3, 179, 180, 181, 182, 183 or 184.

NOV 6 2007

REMARKS

Claims 1, 3, 5, 179-184, 186, 187, 189, 192, 193, 195, 201, 204-212, 222-227, 231-233, 241, 242, 244, 245, 250, 280-299, 303 and 305-324 are currently pending in this application. Claims 1, 3, 5, 179 and 308 have been amended herein to more particularly point out and distinctly claim the invention. No new matter has been added by way of this amendment, and support can be found throughout the specification, *e.g.*, at page 8, line 21 – page 9, line 9; Table 2 (page 47 – 50); and page 67, lines 18-20. After entry of this amendment, claims 1, 3, 5, 179-184, 186, 187, 189, 192, 193, 195, 201, 204-212, 222-227, 231-233, 241, 242, 244, 245, 250, 280-299, 303 and 305-324 will be pending in this application.

The specification has been amended to replace Table 3 to correct minor typographical errors with respect to SEQ ID NOS. of the corresponding CDR sequences as provided in the Sequence Listing. In particular, SEQ ID NO:95 was inadvertently listed twice in Table 3, thereby causing following SEQ ID NOS. to be off by one. Thus, the first instance of SEQ ID NO:95 and SEQ ID NOS:96-99 were changed to SEQ ID NOS:96-100, respectively, and now correctly correspond to the sequences presented in the Sequence Listing. Also, SEQ ID NO:142, 143 and 144 have been renumbered as 143, 144 and 142, respectively, and now correctly correspond to the sequences presented in the Sequence Listing. No new matter has been added by way of this amendment.

The specification has also been amended to clarify that the A4B4 antibody used in the Examples is an A4B4 antibody distinct from the A4B4 antibody identified in Table 2. Thus, the references in the Examples section to antibody “A4B4” have been changed to “A4B4(1) (sequence not shown)” for purposes of clarification. No new matter has been added by way of this amendment.

The specification has also been amended to correct typographical errors on page 119, lines 2-4 (as amended December 5, 2001, page 31) that the framework sequences of antibodies 1X-493L2FR, H3-3F4, M3H9, Y10H6, DG, *AFFF, 6H8, L1-7E5, L2-15B10, *P12F2, *P12F4, *P11d4, *Ale9, *A12a6, *A13a11, and *A13c4 are those depicted in

NOV 6 2007

Figure 2 (not Figure 1). No new matter has been added by way of this amendment, and support can be found in the originally filed specification, *e.g.*, at page 67, lines 18-20. The specification has also been amended to correct typographical errors on page 119, lines 2-4 (as amended December 5, 2001, page 31) that only SYNAGIS® (not AFFF, P12F2, P12F4, P11d4, Ale9, A12a6, A13c4, A17d4, A4B4 and A8c7) has the framework of Figure 1. No new matter has been added by way of this amendment, and support can be found in the originally filed specification, *e.g.*, at page 119, lines 2-7.

The specification has also been amended to insert a substitute Sequence Listing, including new SEQ ID NOS 205 and 206, as well as corrections to SEQ ID NOS:33, 44, 46, 68, 75 and 111. No new matter has been added by way of this amendment, and support can be found in the originally filed specification. New SEQ ID NOS: 205 and 206 correspond the amino acid sequences depicted in Figures 2A and 2B, respectively. SEQ ID NO:33 (Ale9 VH domain) has been corrected at position 32 (Pro-->Ala) in the VH CDR1 to correspond with the Ale9 VH CDR1 sequence shown in Table 2. SEQ ID NO:44 (A17d4 VH domain) has been corrected at position 57 (Gly-->Asp) in VH CDR2 to correspond with the A17d4 VH CDR2 sequence shown in Table 2. SEQ ID NO:46 (A17d4 VL domain) has been corrected at position 24 (Ser-->Leu) in the VL CDR1 to correspond with the A17d4 VL CDR1 sequence shown in Table 2. SEQ ID NO:68 (A13a11 VL domain) has been corrected at position 25 (Ala-->Pro) in VL CDR1, position 28 (Ser-->Arg) in VL CDR1, and position 54 (Ala-->Ser) in VL CDR2 to correspond with the A13a11 VL CDR1 and CDR2 sequences shown in Table 2. SEQ ID NO:75 (A4B4 VL domain) has been corrected at positions 51 and 52 (Phe Phe-->Leu Leu) in the VL CDR2 to correspond with the A4B4 VL CDR2 sequence shown in Table 2. Finally, SEQ ID NO:111 (a VL CDR1) has been corrected at position 4 (Leu-->Ser) to correspond with the VL CDR1 sequence shown in Table 3.

In view of the foregoing amendments and remarks, Applicants respectfully submit that this application is in condition for immediate allowance. If the Examiner disagrees, Applicants respectfully request that the Examiner call the undersigned at the number listed below.

NOV 6 2007

U.S. Serial No. 09/724,531
RCE and Amendment dated November 21, 2006
Page 29 of 29

A Request for Continued Examination (RCE) Transmittal is also submitted herewith, which authorizes the PTO to deduct the RCE fee of \$790 to Jones Day Deposit Account No. 50-3013. Applicants believe no other fees are due in connection with this RCE and response. However, if there are any other fees due, please charge them to Deposit Account 50-3013. If a fee is required for an extension of time under 37 C.F.R. § 1.136, such an extension is requested and the fee should be charged to our Deposit Account. Also, please charge any fees underpaid or credit any fees overpaid to the same Deposit Account.

Respectfully submitted,



Date: Nov. 21, 2006

Fax: Anthony M. Insogna
Tamera M. Pertmer, Ph.D. (Reg. No. 47,856)
JONES DAY
12750 High Bluff Drive, Suite 300
San Diego, CA 92130
(858) 314-1181

For: Anthony M. Insogna (Reg. No. 35,203)
JONES DAY
222 East 41st Street
New York, NY 10017-6702
(212) 326-3939

NOV 6 2007

APPENDIX B:

SUBSTITUTE SEQUENCE LISTING

DATED NOVEMBER 21, 2006

NOV 6 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Young *et al*

Confirmation No.: 7010

Serial No.: 09/724,531

Art Unit: 1648

Filed: November 28, 2000

Examiner: Stacy Brown Chen

For: METHODS OF ADMINISTERING/DOSING
ANTI-RSV ANTIBODIES FOR
PROPHYLAXIS AND TREATMENT

Attorney Docket No: 10271-021-999
(CAM: 209073-999020)

TRANSMITTAL OF SUBSTITUTE SEQUENCE LISTING

Commissioner For Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In connection with the above-identified application, and in accordance with 37 C.F.R. § 1.821, Applicants submit herewith a Substitute Sequence Listing in paper and computer-readable format pursuant to 37 C.F.R. § 1.821(c) and (e).

In accordance with 37 C.F.R. § 1.821(f), the undersigned hereby states that the content of the substitute sequence listing information recorded in computer readable form is identical to the written sequence listing. In accordance with 37 C.F.R. § 1.821(g), the undersigned further states that the written and the computer readable forms of the substitute sequence listing do not include new matter.

Accordingly, Applicant respectfully requests that the substitute sequence listing replace the sequence listing originally filed and be entered into the present application file.

Respectfully submitted,

Date: Nov. 21, 2006

[Signature]
For: Anthony M. Insogna

Tamera M. Pertmer, Ph.D.

(Reg. No. 47,856)

JONES DAY

12750 High Bluff Drive, Suite 300

San Diego, CA 92130

(858) 314-1181

For: Anthony M. Insogna

(Reg. No. 35,203)

JONES DAY

222 East 41st Street

New York, NY 10017

(212) 326-3939

Enclosure



10271-021-999 - Substitute Sequence Listing.txt
SEQUENCE LISTING

<110> Young, James
Koenig, Scott
Leslie, Johnson

<120> Methods of Administering/Dosing Anti-RSV Antibodies for Prophylaxis
and Treatment

<130> 10271-021-999

<140> 09/724,531

<141> 2000-11-28

<160> 206

<170> PatentIn version 3.1

<210> 1

<211> 7

<212> PRT

<213> Homo sapiens

<400> 1

Thr Ser Gly Met Ser Val Gly
1 5

<210> 2

<211> 16

<212> PRT

<213> Homo sapiens

<400> 2

Asp Ile Trp Trp Asp Asp Lys Lys Asp Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15

<210> 3

<211> 10

<212> PRT

<213> Homo sapiens

<400> 3

Ser Met Ile Thr Asn Trp Tyr Phe Asp Val
1 5 10

<210> 4

<211> 10

<212> PRT

<213> Homo sapiens

<400> 4

Lys Cys Gln Leu Ser Val Gly Tyr Met His
1 5 10

<210> 5

<211> 7

<212> PRT

<213> Homo sapiens

<400> 5

Asp Thr Ser Lys Leu Ala Ser
1 5

10271-021-999 - Substitute Sequence Listing.txt

<210> 6
 <211> 9
 <212> PRT
 <213> Homo sapiens

<400> 6
 Phe Gln Gly Ser Gly Tyr Pro Phe Thr
 1 5

<210> 7
 <211> 120
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> VH Domain

<400> 7
 Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
 1 5 10 15
 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
 20 25 30
 Gly Met Ser Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
 35 40 45
 Trp Leu Ala Asp Ile Trp Trp Asp Asp Lys Lys Asp Tyr Asn Pro Ser
 50 55 60
 Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
 65 70 75 80
 Val Leu Lys Val Thr Asn Met Asp Pro Ala Asp Thr Ala Thr Tyr Tyr
 85 90 95
 Cys Ala Arg Ser Met Ile Thr Asn Trp Tyr Phe Asp Val Trp Gly Ala
 100 105 110
 Gly Thr Thr Val Thr Val Ser Ser
 115 120

<210> 8
 <211> 106
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> VL Domain

<400> 8
 Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Lys Cys Gln Leu Ser Val Gly Tyr Met
 20 25 30
 His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
 35 40 45
 Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
 Page 2

10271-021-999 - Substitute Sequence Listing.txt

50

55

60

Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Gly Tyr Pro Phe Thr
85 90 95
Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105

<210> 9
<211> 120
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> VH Domain

<400> 9
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ala
20 25 30
Gly Met Ser Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
35 40 45
Trp Leu Ala Asp Ile Trp Trp Asp Asp Lys Lys Asp Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
65 70 75 80
Val Leu Lys Val Thr Asn Met Asp Pro Ala Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Arg Ser Met Ile Thr Asn Phe Tyr Phe Asp Val Trp Gly Ala
100 105 110
Gly Thr Thr Val Thr Val Ser Ser
115 120

<210> 10
<211> 7
<212> PRT
<213> Homo sapiens

<400> 10
Thr Ala Gly Met Ser Val Gly
1 5

<210> 11
<211> 10
<212> PRT
<213> Homo sapiens

<400> 11
Ser Met Ile Thr Asn Phe Tyr Phe Asp Val
1 5 10

10271-021-999 - Substitute Sequence Listing.txt

<210> 12
 <211> 106
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> VL Domain

<400> 12
 Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Gly Tyr Met
 20 25 30
 His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
 35 40 45
 Asp Thr Phe Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
 50 55 60
 Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
 65 70 75 80
 Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Phe Tyr Pro Phe Thr
 85 90 95
 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105

<210> 13
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 13
 Ser Ala Ser Ser Ser Val Gly Tyr Met His
 1 5 10

<210> 14
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 14
 Asp Thr Phe Lys Leu Ala Ser
 1 5

<210> 15
 <211> 9
 <212> PRT
 <213> Homo sapiens

<400> 15
 Phe Gln Gly Ser Phe Tyr Pro Phe Thr
 1 5

<210> 16
 <211> 120
 <212> PRT

10271-021-999 - Substitute Sequence Listing.txt

<213> Homo sapiens

<220>

<221> misc_feature

<223> VH Domain

<400> 16

Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15

Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Pro
20 25 30

Gly Met Ser Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
35 40 45

Trp Leu Ala Asp Ile Trp Trp Asp Asp Lys Lys His Tyr Asn Pro Ser
50 55 60

Leu Lys Asp Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
65 70 75 80

Val Leu Lys Val Thr Asn Met Asp Pro Ala Asp Thr Ala Thr Tyr Tyr
85 90 95

Cys Ala Arg Asp Met Ile Phe Asn Phe Tyr Phe Asp Val Trp Gly Gln
100 105 110

Gly Thr Thr Val Thr Val Ser Ser
115 120

<210> 17

<211> 7

<212> PRT

<213> Homo sapiens

<400> 17

Thr Pro Gly Met Ser Val Gly
1 5

<210> 18

<211> 16

<212> PRT

<213> Homo sapiens

<400> 18

Asp Ile Trp Trp Asp Asp Lys Lys His Tyr Asn Pro Ser Leu Lys Asp
1 5 10 15

<210> 19

<211> 10

<212> PRT

<213> Homo sapiens

<400> 19

Asp Met Ile Phe Asn Phe Tyr Phe Asp Val
1 5 10

<210> 20

<211> 106

<212> PRT

<213> Homo sapiens

10271-021-999 - Substitute Sequence Listing.txt

<220>

<221> misc_feature

<223> VL Domain

<400> 20

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Ser Leu Ser Ser Arg Val Gly Tyr Met
20 25 30

His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
35 40 45

Asp Thr Phe Tyr Leu Ser Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60

Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
65 70 75 80

Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Gly Tyr Pro Phe Thr
85 90 95

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105

<210> 21

<211> 10

<212> PRT

<213> Homo sapiens

<400> 21

Ser Leu Ser Ser Arg Val Gly Tyr Met His
1 5 10

<210> 22

<211> 7

<212> PRT

<213> Homo sapiens

<400> 22

Asp Thr Phe Tyr Leu Ser Ser
1 5

<210> 23

<211> 120

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> VH Domain

<400> 23

Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15

Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Pro
20 25 30

Gly Met Ser Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
35 40 45

10271-021-999 - Substitute Sequence Listing.txt

Trp Leu Ala Asp Ile Trp Trp Asp Gly Lys Lys His Tyr Asn Pro Ser
50 55 60

Leu Lys Asp Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
65 70 75 80

Val Leu Lys Val Thr Asn Met Asp Pro Ala Asp Thr Ala Thr Tyr Tyr
85 90 95

Cys Ala Arg Asp Met Ile Phe Asn Phe Tyr Phe Asp Val Trp Gly Gln
100 105 110

Gly Thr Thr Val Thr Val Ser Ser
115 120

<210> 24
<211> 16
<212> PRT
<213> Homo sapiens

<400> 24
Asp Ile Trp Trp Asp Gly Lys Lys His Tyr Asn Pro Ser Leu Lys Asp
1 5 10 15

<210> 25
<211> 106
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> VL Domain

<400> 25
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Ser Leu Ser Ser Arg Val Gly Tyr Met
20 25 30

His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
35 40 45

Asp Thr Arg Gly Leu Pro Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60

Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
65 70 75 80

Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Gly Tyr Pro Phe Thr
85 90 95

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105

<210> 26
<211> 10
<212> PRT
<213> Homo sapiens

<400> 26
Asp Met Ile Thr Asn Phe Tyr Phe Asp Val
1 5 10

10271-021-999 - Substitute Sequence Listing.txt

<210> 27
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 27
 Asp Thr Arg Gly Leu Pro Ser
 1 5

<210> 28
 <211> 120
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> VH Domain

<400> 28
 Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
 1 5 10 15
 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Pro
 20 25 30
 Gly Met Ser Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
 35 40 45
 Trp Leu Ala Asp Ile Trp Trp Asp Gly Lys Lys His Tyr Asn Pro Ser
 50 55 60
 Leu Lys Asp Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
 65 70 75 80
 Val Leu Lys Val Thr Asn Met Asp Pro Ala Asp Thr Ala Thr Tyr Tyr
 85 90 95
 Cys Ala Arg Asp Met Ile Phe Asn Trp Tyr Phe Asp Val Trp Gly Gln
 100 105 110
 Gly Thr Thr Val Thr Val Ser Ser
 115 120

<210> 29
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 29
 Asp Met Ile Phe Asn Trp Tyr Phe Asp Val
 1 5 10

<210> 30
 <211> 106
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> VL Domain

<400> 30

10271-021-999 - Substitute Sequence Listing.txt

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Ser Pro Ser Ser Arg Val Gly Tyr Met
 20 25 30
 His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
 35 40 45
 Asp Thr Met Arg Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
 50 55 60
 Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
 65 70 75 80
 Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Gly Tyr Pro Phe Thr
 85 90 95
 Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 31
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 31
 Ser Pro Ser Ser Arg Val Gly Tyr Met His
 1 5 10

<210> 32
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 32
 Asp Thr Met Arg Leu Ala Ser
 1 5

<210> 33
 <211> 120
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> VH Domain

<400> 33
 Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
 1 5 10 15
 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ala
 20 25 30
 Gly Met Ser Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
 35 40 45
 Trp Leu Ala Asp Ile Trp Trp Asp Gly Lys Lys His Tyr Asn Pro Ser
 50 55 60
 Leu Lys Asp Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
 Page 9

NOV 6 2007

10271-021-999 - Substitute Sequence Listing.txt

65

70

75

80

Val Leu Lys Val Thr Asn Met Asp Pro Ala Asp Thr Ala Thr Tyr Tyr
85 90 95

Cys Ala Arg Asp Met Ile Phe Asn Trp Tyr Phe Asp Val Trp Gly Gln
100 105 110

Gly Thr Thr Val Thr Val Ser Ser
115 120

<210> 34
<211> 106
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> VL Domain

<400> 34
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Ser Leu Ser Ser Arg Val Gly Tyr Met
20 25 30

His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
35 40 45

Asp Thr Phe Lys Leu Ser Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60

Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
65 70 75 80

Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Gly Tyr Pro Phe Thr
85 90 95

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105

<210> 35
<211> 7
<212> PRT
<213> Homo sapiens

<400> 35
Asp Thr Phe Lys Leu Ser Ser
1 5

<210> 36
<211> 120
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> VH Domain

<400> 36
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln

10271-021-999 - Substitute Sequence Listing.txt

```

1          5          10          15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ala
      20      25      30
Gly Met Ser Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
      35      40      45
Trp Leu Ala Asp Ile Trp Trp Asp Gly Lys Lys Asp Tyr Asn Pro Ser
      50      55      60
Leu Lys Asp Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
      65      70      75      80
Val Leu Lys Val Thr Asn Met Asp Pro Ala Asp Thr Ala Thr Tyr Tyr
      85      90      95
Cys Ala Arg Asp Met Ile Phe Asn Phe Tyr Phe Asp Val Trp Gly Gln
      100      105      110
Gly Thr Thr Val Thr Val Ser Ser
      115      120

<210> 37
<211> 16
<212> PRT
<213> Homo sapiens

<400> 37
Asp Ile Trp Trp Asp Gly Lys Lys Asp Tyr Asn Pro Ser Leu Lys Asp
1          5          10          15

<210> 38
<211> 106
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> VL Domain

<400> 38
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1          5          10          15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Arg Val Gly Tyr Met
      20      25      30
His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
      35      40      45
Asp Thr Phe Lys Leu Ser Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
      50      55      60
Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
      65      70      75      80
Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Gly Tyr Pro Phe Thr
      85      90      95
Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
      100      105

```

NOV 6 2007

10271-021-999 - Substitute Sequence Listing.txt

<210> 39
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 39
 Ser Ala Ser Ser Arg Val Gly Tyr Met His
 1 5 10

<210> 40
 <211> 120
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> VH Domain

<400> 40
 Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
 1 5 10 15
 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ala
 20 25 30
 Gly Met Ser Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
 35 40 45
 Trp Leu Ala Asp Ile Trp Trp Asp Gly Lys Lys Ser Tyr Asn Pro Ser
 50 55 60
 Leu Lys Asp Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
 65 70 75 80
 Val Leu Lys Val Thr Asn Met Asp Pro Ala Asp Thr Ala Thr Tyr Tyr
 85 90 95
 Cys Ala Arg Asp Met Ile Phe Asn Phe Tyr Phe Asp Val Trp Gly Gln
 100 105 110
 Gly Thr Thr Val Thr Val Ser Ser
 115 120

<210> 41
 <211> 16
 <212> PRT
 <213> Homo sapiens

<400> 41
 Asp Ile Trp Trp Asp Gly Lys Lys Ser Tyr Asn Pro Ser Leu Lys Asp
 1 5 10 15

<210> 42
 <211> 106
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> VL Domain

<400> 42
 Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly

10271-021-999 - Substitute Sequence Listing.txt

1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Ser Leu Ser Ser Arg Val Gly Tyr Met
 20 25 30
 His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
 35 40 45
 Asp Thr Met Tyr Gln Ser Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
 50 55 60
 Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
 65 70 75 80
 Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Gly Tyr Pro Phe Thr
 85 90 95
 Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 43
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 43
 Asp Thr Met Tyr Gln Ser Ser
 1 5

<210> 44
 <211> 120
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> VH Domain

<400> 44
 Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
 1 5 10 15
 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ala
 20 25 30
 Gly Met Ser Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
 35 40 45
 Trp Leu Ala Asp Ile Trp Trp Asp Asp Lys Lys Ser Tyr Asn Pro Ser
 50 55 60
 Leu Lys Asp Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
 65 70 75 80
 Val Leu Lys Val Thr Asn Met Asp Pro Ala Asp Thr Ala Thr Tyr Tyr
 85 90 95
 Cys Ala Arg Asp Met Ile Phe Asn Phe Tyr Phe Asp Val Trp Gly Gln
 100 105 110
 Gly Thr Thr Val Thr Val Ser Ser
 115 120

10271-021-999 - Substitute Sequence Listing.txt

<210> 45
 <211> 16
 <212> PRT
 <213> Homo sapiens

<400> 45
 Asp Ile Trp Trp Asp Asp Lys Lys Ser Tyr Asn Pro Ser Leu Lys Asp
 1 5 10 15

<210> 46
 <211> 106
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> VL Domain

<400> 46
 Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
 1 5 10 15

Asp Arg Val Thr Ile Thr Cys Leu Pro Ser Ser Arg Val Gly Tyr Met
 20 25 30

His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
 35 40 45

Asp Thr Met Tyr Gln Ser Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
 50 55 60

Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
 65 70 75 80

Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Gly Tyr Pro Phe Thr
 85 90 95

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
 100 105

<210> 47
 <211> 11
 <212> PRT
 <213> Homo sapiens

<400> 47
 Leu Pro Ser Ser Arg Val Gly Tyr Met His Trp
 1 5 10

<210> 48
 <211> 120
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> VH Domain

<400> 48
 Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
 1 5 10 15

10271-021-999 - Substitute Sequence Listing.txt

Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ala
 20 25 30
 Gly Met Ser Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
 35 40 45
 Trp Leu Ala Asp Ile Trp Trp Asp Asp Lys Lys His Tyr Asn Pro Ser
 50 55 60
 Leu Lys Asp Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
 65 70 75 80
 Val Leu Lys Val Thr Asn Met Asp Pro Ala Asp Thr Ala Thr Tyr Tyr
 85 90 95
 Cys Ala Arg Asp Met Ile Phe Asn Phe Tyr Phe Asp Val Trp Gly Gln
 100 105 110
 Gly Thr Thr Val Thr Val Ser Ser
 115 120

<210> 49
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 49
 Asp Thr Phe Tyr Leu Ser Ser
 1 5

<210> 50
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 50
 Asp Thr Leu Leu Leu Asp Ser
 1 5

<210> 51
 <211> 120
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> VH Domain

<400> 51
 Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
 1 5 10 15

Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ala
 20 25 30

Gly Met Ser Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
 35 40 45

Trp Leu Ala Asp Ile Trp Trp Asp Asp Lys Lys Ser Tyr Asn Pro Ser
 50 55 60

Leu Lys Asp Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
 65 70 75 80

10271-021-999 - Substitute Sequence Listing.txt

Val Leu Lys Val Thr Asn Met Asp Pro Ala Asp Thr Ala Thr Tyr Tyr
85 90 95

Cys Ala Arg Asp Met Ile Phe Asn Trp Tyr Phe Asp Val Trp Gly Gln
100 105 110

Gly Thr Thr Val Thr Val Ser Ser
115 120

<210> 52
<211> 106
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> VL Domain

<400> 52
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Ser Pro Ser Ser Arg Val Gly Tyr Met
20 25 30

His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
35 40 45

Asp Thr Arg Tyr Gln Ser Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60

Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
65 70 75 80

Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Gly Tyr Pro Phe Thr
85 90 95

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105

<210> 53
<211> 11
<212> PRT
<213> Homo sapiens

<400> 53
Ser Pro Ser Ser Arg Val Gly Tyr Met His Trp
1 5 10

<210> 54
<211> 7
<212> PRT
<213> Homo sapiens

<400> 54
Asp Thr Arg Tyr Gln Ser Ser
1 5

<210> 55
<211> 106
<212> PRT

NOV 6 2007

10271-021-999 - Substitute Sequence Listing.txt

<213> Homo sapiens

<220>

<221> misc_feature

<223> VL Domain

<400> 55

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Gly Tyr Met
20 25 30

His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
35 40 45

Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60

Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
65 70 75 80

Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Gly Tyr Pro Phe Thr
85 90 95

Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105

<210> 56

<211> 120

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> VH Domain

<400> 56

Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15

Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ala
20 25 30

Gly Met Ser Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
35 40 45

Trp Leu Ala Asp Ile Trp Trp Asp Asp Lys Lys Asp Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
65 70 75 80

Val Leu Lys Val Thr Asn Met Asp Pro Ala Asp Thr Ala Thr Tyr Tyr
85 90 95

Cys Ala Arg Asp Met Ile Phe Asn Trp Tyr Phe Asp Val Trp Gly Ala
100 105 110

Gly Thr Thr Val Thr Val Ser Ser
115 120

10271-021-999 - Substitute Sequence Listing.txt

<210> 57
 <211> 106
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> VL Domain

<400> 57
 Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Gly Tyr Met
 20 25 30
 His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
 35 40 45
 Asp Thr Phe Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
 50 55 60
 Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
 65 70 75 80
 Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Gly Tyr Pro Phe Thr
 85 90 95
 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105

<210> 58
 <211> 106
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> VL Domain

<400> 58
 Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Gly Tyr Met
 20 25 30
 His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
 35 40 45
 Asp Thr Tyr Lys Gln Thr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
 50 55 60
 Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
 65 70 75 80
 Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Gly Tyr Pro Phe Thr
 85 90 95
 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105

<210> 59

10271-021-999 - Substitute Sequence Listing.txt

<211> 7
<212> PRT
<213> Homo sapiens

<400> 59
Asp Thr Tyr Lys Gln Thr Ser
1 5

<210> 60
<211> 106
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> VL Domain

<400> 60
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Gly Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
35 40 45
Asp Thr Arg Tyr Leu Ser Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Gly Tyr Pro Phe Thr
85 90 95
Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105

<210> 61
<211> 7
<212> PRT
<213> Homo sapiens

<400> 61
Asp Thr Arg Tyr Leu Ser Ser
1 5

<210> 62
<211> 106
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> VL Domain

<400> 62
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Gly Tyr Met
20 25 30

10271-021-999 - Substitute Sequence Listing.txt

His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
 35 40 45
 Asp Thr Phe Lys Leu Thr Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
 50 55 60
 Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
 65 70 75 80
 Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Gly Tyr Pro Phe Thr
 85 90 95
 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105

<210> 63
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 63
 Asp Thr Phe Lys Leu Thr Ser
 1 5

<210> 64
 <211> 106
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> VL Domain

<400> 64
 Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Arg Val Gly Tyr Met
 20 25 30
 His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
 35 40 45
 Asp Thr Phe Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
 50 55 60
 Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
 65 70 75 80
 Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Gly Tyr Pro Phe Thr
 85 90 95
 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105

<210> 65
 <211> 106
 <212> PRT
 <213> Homo sapiens

<220>

10271-021-999 - Substitute Sequence Listing.txt

<221> misc_feature

<223> VL Domain

<400> 65

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Gly Tyr Met
20 25 30

His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
35 40 45

Asp Thr Phe Arg Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60

Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
65 70 75 80

Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Gly Tyr Pro Phe Thr
85 90 95

Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105

<210> 66

<211> 7

<212> PRT

<213> Homo sapiens

<400> 66

Asp Thr Phe Arg Leu Ala Ser
1 5

<210> 67

<211> 120

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> VH Domain

<400> 67

Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15

Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ala
20 25 30

Gly Met Ser Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
35 40 45

Trp Leu Ala Asp Ile Trp Trp Asp Asp Lys Lys His Tyr Asn Pro Ser
50 55 60

Leu Lys Asp Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
65 70 75 80

Val Leu Lys Val Thr Asn Met Asp Pro Ala Asp Thr Ala Thr Tyr Tyr
85 90 95

10271-021-999 - Substitute Sequence Listing.txt

Cys Ala Arg Asp Met Ile Phe Asn Trp Tyr Phe Asp Val Trp Gly Ala
100 105 110

Gly Thr Thr Val Thr Val Ser Ser
115 120

<210> 68
<211> 106
<212> PRT
<213> Homo sapiens
<220>
<221> misc_feature
<223> VL Domain

<400> 68
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Ser Pro Ser Ser Arg Val Gly Tyr Met
20 25 30

His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
35 40 45

Asp Thr Tyr Arg His Ser Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60

Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
65 70 75 80

Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Gly Tyr Pro Phe Thr
85 90 95

Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105

<210> 69
<211> 7
<212> PRT
<213> Homo sapiens

<400> 69
Asp Thr Tyr Arg His Ser Ser
1 5

<210> 70
<211> 106
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> VL Domain

<400> 70
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Ser Leu Ser Ser Ser Val Gly Tyr Met
20 25 30

His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
Page 22

NOV 6 2007

10271-021-999 - Substitute Sequence Listing.txt

35 40 45
 Asp Thr Phe Phe His Arg Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
 50 55 60
 Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
 65 70 75 80
 Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Gly Tyr Pro Phe Thr
 85 90 95
 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105

<210> 71
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 71
 Ser Leu Ser Ser Ser Val Gly Tyr Met His
 1 5 10

<210> 72
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 72
 Asp Thr Phe Phe His Arg Ser
 1 5

<210> 73
 <211> 11
 <212> PRT
 <213> Homo sapiens

<400> 73
 Ser Ala Ser Ser Arg Val Gly Tyr Met His Trp
 1 5 10

<210> 74
 <211> 120
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> VH Domain

<400> 74
 Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
 1 5 10 15
 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ala
 20 25 30
 Gly Met Ser Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
 35 40 45
 Trp Leu Ala Asp Ile Trp Trp Asp Asp Lys Lys Asp Tyr Asn Pro Ser
 50 55 60

10271-021-999 - Substitute Sequence Listing.txt

Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
65 70 75 80
Val Leu Lys Val Thr Asn Met Asp Pro Ala Asp Thr Ala Thr Tyr Tyr
85 90 95
Cys Ala Arg Asp Met Ile Thr Asn Phe Tyr Phe Asp Val Trp Gly Ala
100 105 110
Gly Thr Thr Val Thr Val Ser Ser
115 120

<210> 75
<211> 106
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> VL Domain

<400> 75
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Arg Val Gly Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
35 40 45
Asp Thr Leu Leu Leu Asp Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Gly Tyr Pro Phe Thr
85 90 95
Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105

<210> 76
<211> 10
<212> PRT
<213> Homo sapiens

<400> 76
Asp Met Ile Thr Asn Phe Tyr Phe Asp Val
1 5 10

<210> 77
<211> 10
<212> PRT
<213> Homo sapiens

<400> 77
Lys Cys Gln Ser Ser Val Gly Tyr Met His
1 5 10

<210> 78

10271-021-999 - Substitute Sequence Listing.txt

<211> 7
 <212> PRT
 <213> Homo sapiens

<400> 78
 Asp Thr Ser Tyr Leu Ala Ser
 1 5

<210> 79
 <211> 16
 <212> PRT
 <213> Homo sapiens

<400> 79
 Asp Ile Trp Trp Asp Asp Lys Lys His Tyr Asn Pro Ser Leu Lys Ser
 1 5 10 15

<210> 80
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 80
 Asp Met Ile Thr Asn Trp Tyr Phe Asp Val
 1 5 10

<210> 81
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 81
 Lys Cys Gln Ser Arg Val Gly Tyr Met His
 1 5 10

<210> 82
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 82
 Asp Thr Ser Tyr Leu Ser Ser
 1 5

<210> 83
 <211> 16
 <212> PRT
 <213> Homo sapiens

<400> 83
 Asp Ile Trp Trp Asp Asp Lys Lys Asp Tyr Asn Pro Ser Leu Lys Asp
 1 5 10 15

<210> 84
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 84
 Lys Cys Gln Leu Arg Val Gly Tyr Met His
 1 5 10

<210> 85

10271-021-999 - Substitute Sequence Listing.txt

<211> 7
 <212> PRT
 <213> Homo sapiens

<400> 85
 Asp Thr Lys Lys Leu Ser Ser
 1 5

<210> 86
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 86
 Lys Leu Gln Leu Ser Val Gly Tyr Met His
 1 5 10

<210> 87
 <211> 16
 <212> PRT
 <213> Homo sapiens

<400> 87
 Asp Ile Trp Trp Asp Asp Lys Lys His Tyr Asn Pro Ser Leu Lys Ser
 1 5 10 15

<210> 88
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 88
 Lys Leu Gln Ser Ser Val Gly Tyr Met His
 1 5 10

<210> 89
 <211> 16
 <212> PRT
 <213> Homo sapiens

<400> 89
 Asp Ile Trp Trp Asp Asp Lys Lys Asp Tyr Asn Pro Ser Leu Lys Asp
 1 5 10 15

<210> 90
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 90
 Ser Met Ile Phe Asn Trp Tyr Phe Asp Val
 1 5 10

<210> 91
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 91
 Lys Leu Gln Ser Arg Val Gly Tyr Met His
 1 5 10

<210> 92

10271-021-999 - Substitute Sequence Listing.txt

<211> 10
<212> PRT
<213> Homo sapiens

<400> 92
Ser Met Ile Phe Asn Phe Tyr Phe Asp Val
1 5 10

<210> 93
<211> 10
<212> PRT
<213> Homo sapiens

<400> 93
Lys Leu Gln Leu Arg Val Gly Tyr Met His
1 5 10

<210> 94
<211> 7
<212> PRT
<213> Homo sapiens

<400> 94
Asp Thr Phe Tyr Leu Ala Ser
1 5

<210> 95
<211> 16
<212> PRT
<213> Homo sapiens

<400> 95
Asp Ile Trp Trp Asp Gly Lys Lys His Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15

<210> 96
<211> 16
<212> PRT
<213> Homo sapiens

<400> 96
Asp Ile Trp Trp Asp Gly Lys Lys Asp Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15

<210> 97
<211> 10
<212> PRT
<213> Homo sapiens

<400> 97
Lys Leu Ser Leu Ser Val Gly Tyr Met His
1 5 10

<210> 98
<211> 7
<212> PRT
<213> Homo sapiens

<400> 98
Asp Thr Ser Lys Leu Pro Ser
1 5

<210> 99

10271-021-999 - Substitute Sequence Listing.txt

<211> 10
<212> PRT
<213> Homo sapiens

<400> 99
Lys Leu Ser Ser Val Gly Tyr Met His
1 5 10

<210> 100
<211> 7
<212> PRT
<213> Homo sapiens

<400> 100
Asp Thr Ser Gly Leu Ala Ser
1 5

<210> 101
<211> 10
<212> PRT
<213> Homo sapiens

<400> 101
Lys Leu Ser Ser Arg Val Gly Tyr Met His
1 5 10

<210> 102
<211> 7
<212> PRT
<213> Homo sapiens

<400> 102
Asp Thr Ser Gly Leu Pro Ser
1 5

<210> 103
<211> 16
<212> PRT
<213> Homo sapiens

<400> 103
Asp Ile Trp Trp Asp Asp Lys Lys Ser Tyr Asn Pro Ser Leu Lys Ser
1 5 10 15

<210> 104
<211> 10
<212> PRT
<213> Homo sapiens

<400> 104
Lys Leu Ser Leu Arg Val Gly Tyr Met His
1 5 10

<210> 105
<211> 16
<212> PRT
<213> Homo sapiens

<400> 105
Asp Ile Trp Trp Asp Asp Lys Lys Ser Tyr Asn Pro Ser Leu Lys Asp
1 5 10 15

<210> 106

10271-021-999 - Substitute Sequence Listing.txt

<211> 10
 <212> PRT
 <213> Homo sapiens

<400> 106
 Lys Cys Ser Leu Ser Val Gly Tyr Met His
 1 5 10

<210> 107
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 107
 Asp Thr Arg Lys Leu Ala Ser
 1 5

<210> 108
 <211> 16
 <212> PRT
 <213> Homo sapiens

<400> 108
 Asp Ile Trp Trp Asp Gly Lys Lys Ser Tyr Asn Pro Ser Leu Lys Ser
 1 5 10 15

<210> 109
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 109
 Lys Cys Ser Ser Ser Val Gly Tyr Met His
 1 5 10

<210> 110
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 110
 Asp Thr Arg Gly Leu Ala Ser
 1 5

<210> 111
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 111
 Lys Cys Ser Ser Arg Val Gly Tyr Met His
 1 5 10

<210> 112
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 112
 Asp Thr Arg Lys Leu Pro Ser
 1 5

<210> 113

10271-021-999 - Substitute Sequence Listing.txt

<211> 10
 <212> PRT
 <213> Homo sapiens
 <400> 113
 Lys Cys Ser Leu Arg Val Gly Tyr Met His
 1 5 10

<210> 114
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 114
 Ser Leu Ser Leu Ser Val Gly Tyr Met His
 1 5 10

<210> 115
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 115
 Asp Thr Met Lys Leu Ala Ser
 1 5

<210> 116
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 116
 Ser Leu Ser Ser Ser Val Gly Tyr Met His
 1 5 10

<210> 117
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 117
 Asp Thr Ser Arg Leu Ala Ser
 1 5

<210> 118
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 118
 Asp Thr Ser Leu Leu Ala Ser
 1 5

<210> 119
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 119
 Ser Leu Ser Leu Arg Val Gly Tyr Met His
 1 5 10

<210> 120

10271-021-999 - Substitute Sequence Listing.txt

```

<211> 7
<212> PRT
<213> Homo sapiens

<400> 120
Asp Thr Ser Leu Leu Asp Ser
1      5

<210> 121
<211> 10
<212> PRT
<213> Homo sapiens

<400> 121
Ser Cys Gln Leu Ser Val Gly Tyr Met His
1      5      10

<210> 122
<211> 7
<212> PRT
<213> Homo sapiens

<400> 122
Asp Thr Ser Lys Leu Asp Ser
1      5

<210> 123
<211> 10
<212> PRT
<213> Homo sapiens

<400> 123
Ser Cys Gln Ser Ser Val Gly Tyr Met His
1      5      10

<210> 124
<211> 7
<212> PRT
<213> Homo sapiens

<400> 124
Asp Thr Leu Leu Leu Asp Ser
1      5

<210> 125
<211> 10
<212> PRT
<213> Homo sapiens

<400> 125
Ser Cys Gln Ser Arg Val Gly Tyr Met His
1      5      10

<210> 126
<211> 7
<212> PRT
<213> Homo sapiens

<400> 126
Asp Thr Leu Lys Leu Asp Ser
1      5

<210> 127

```

10271-021-999 - Substitute Sequence Listing.txt

<211> 10
 <212> PRT
 <213> Homo sapiens
 <400> 127
 Ser Cys Gln Leu Arg Val Gly Tyr Met His
 1 5 10

<210> 128
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 128
 Asp Thr Leu Leu Leu Ala Ser
 1 5

<210> 129
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 129
 Ser Leu Gln Leu Ser Val Gly Tyr Met His
 1 5 10

<210> 130
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 130
 Asp Thr Leu Lys Leu Ala Ser
 1 5

<210> 131
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 131
 Ser Leu Gln Ser Ser Val Gly Tyr Met His
 1 5 10

<210> 132
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 132
 Asp Thr Ser Lys Leu Ser Ser
 1 5

<210> 133
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 133
 Ser Leu Gln Ser Arg Val Gly Tyr Met His
 1 5 10

<210> 134

10271-021-999 - Substitute Sequence Listing.txt

<211> 7
 <212> PRT
 <213> Homo sapiens

<400> 134
 Asp Thr Ser Lys Gln Ala Ser
 1 5

<210> 135
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 135
 Ser Leu Gln Leu Arg Val Gly Tyr Met His
 1 5 10

<210> 136
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 136
 Asp Thr Ser Lys Gln Ser Ser
 1 5

<210> 137
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 137
 Ser Cys Ser Leu Ser Val Gly Tyr Met His
 1 5 10

<210> 138
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 138
 Asp Thr Ser Tyr Leu Ala Ser
 1 5

<210> 139
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 139
 Ser Cys Ser Ser Ser Val Gly Tyr Met His
 1 5 10

<210> 140
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 140
 Asp Thr Ser Tyr Leu Ser Ser
 1 5

<210> 141

10271-021-999 - Substitute Sequence Listing.txt

<211> 10
 <212> PRT
 <213> Homo sapiens
 <400> 141
 Ser Cys Ser Ser Arg Val Gly Tyr Met His
 1 5 10

<210> 142
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 142
 Asp Thr Ser Tyr Gln Ser Ser
 1 5

<210> 143
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 143
 Asp Thr Ser Tyr Gln Ala Ser
 1 5

<210> 144
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 144
 Ser Cys Ser Leu Arg Val Gly Tyr Met His
 1 5 10

<210> 145
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 145
 Lys Pro Ser Ser Arg Val Gly Tyr Met His
 1 5 10

<210> 146
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 146
 Asp Thr Met Tyr Gln Ala Ser
 1 5

<210> 147
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 147
 Lys Pro Ser Leu Arg Val Gly Tyr Met His
 1 5 10

<210> 148

10271-021-999 - Substitute Sequence Listing.txt

<211> 10
 <212> PRT
 <213> Homo sapiens
 <400> 148
 Lys Pro Ser Ser Ser Val Gly Tyr Met His
 1 5 10

<210> 149
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 149
 Asp Thr Met Lys Gln Ala Ser
 1 5

<210> 150
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 150
 Lys Pro Ser Leu Ser Val Gly Tyr Met His
 1 5 10

<210> 151
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 151
 Asp Thr Met Lys Gln Ser Ser
 1 5

<210> 152
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 152
 Lys Pro Gln Ser Arg Val Gly Tyr Met His
 1 5 10

<210> 153
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 153
 Asp Thr Met Tyr Leu Ala Ser
 1 5

<210> 154
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 154
 Lys Pro Gln Leu Arg Val Gly Tyr Met His
 1 5 10

<210> 155

10271-021-999 - Substitute Sequence Listing.txt

```

<211> 7
<212> PRT
<213> Homo sapiens

<400> 155
Asp Thr Met Tyr Leu Ser Ser
1          5

<210> 156
<211> 10
<212> PRT
<213> Homo sapiens

<400> 156
Lys Pro Gln Ser Ser Val Gly Tyr Met His
1          5          10

<210> 157
<211> 7
<212> PRT
<213> Homo sapiens

<400> 157
Asp Thr Met Lys Leu Ala Ser
1          5

<210> 158
<211> 10
<212> PRT
<213> Homo sapiens

<400> 158
Lys Pro Gln Leu Ser Val Gly Tyr Met His
1          5          10

<210> 159
<211> 7
<212> PRT
<213> Homo sapiens

<400> 159
Asp Thr Met Lys Leu Ser Ser
1          5

<210> 160
<211> 10
<212> PRT
<213> Homo sapiens

<400> 160
Ser Pro Ser Ser Arg Val Gly Tyr Met His
1          5          10

<210> 161
<211> 7
<212> PRT
<213> Homo sapiens

<400> 161
Asp Thr Ser Lys Leu Ser Ser
1          5

<210> 162

```

10271-021-999 - Substitute Sequence Listing.txt

<211> 10
 <212> PRT
 <213> Homo sapiens

<400> 162
 Ser Pro Ser Leu Arg Val Gly Tyr Met His
 1 5 10

<210> 163
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 163
 Asp Thr Arg Tyr Gln Ala Ser
 1 5

<210> 164
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 164
 Ser Pro Ser Ser Ser Val Gly Tyr Met His
 1 5 10

<210> 165
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 165
 Ser Pro Ser Leu Ser Val Gly Tyr Met His
 1 5 10

<210> 166
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 166
 Asp Thr Arg Lys Gln Ala Ser
 1 5

<210> 167
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 167
 Ser Pro Gln Ser Arg Val Gly Tyr Met His
 1 5 10

<210> 168
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 168
 Asp Thr Arg Lys Gln Ser Ser
 1 5

<210> 169

10271-021-999 - Substitute Sequence Listing.txt

```

<211> 10
<212> PRT
<213> Homo sapiens

<400> 169
Ser Pro Gln Leu Arg Val Gly Tyr Met His
1          5          10

<210> 170
<211> 7
<212> PRT
<213> Homo sapiens

<400> 170
Asp Thr Arg Lys Leu Ala Ser
1          5

<210> 171
<211> 10
<212> PRT
<213> Homo sapiens

<400> 171
Ser Pro Gln Ser Ser Val Gly Tyr Met His
1          5          10

<210> 172
<211> 7
<212> PRT
<213> Homo sapiens

<400> 172
Asp Thr Arg Lys Leu Ser Ser
1          5

<210> 173
<211> 10
<212> PRT
<213> Homo sapiens

<400> 173
Ser Pro Gln Leu Ser Val Gly Tyr Met His
1          5          10

<210> 174
<211> 7
<212> PRT
<213> Homo sapiens

<400> 174
Asp Thr Arg Tyr Leu Ala Ser
1          5

<210> 175
<211> 10
<212> PRT
<213> Homo sapiens

<400> 175
Lys Ala Gln Ser Arg Val Gly Tyr Met His
1          5          10

<210> 176

```

10271-021-999 - Substitute Sequence Listing.txt

<211> 10
 <212> PRT
 <213> Homo sapiens

<400> 176
 Lys Ala Gln Leu Arg Val Gly Tyr Met His
 1 5 10

<210> 177
 <211> 7
 <212> PRT
 <213> Homo sapiens

<400> 177
 Asp Thr Arg Tyr Leu Ser Ser
 1 5

<210> 178
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 178
 Lys Ala Gln Ser Ser Val Gly Tyr Met His
 1 5 10

<210> 179
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 179
 Lys Ala Gln Leu Ser Val Gly Tyr Met His
 1 5 10

<210> 180
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 180
 Lys Ala Ser Ser Arg Val Gly Tyr Met His
 1 5 10

<210> 181
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 181
 Lys Ala Ser Leu Arg Val Gly Tyr Met His
 1 5 10

<210> 182
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 182
 Lys Ala Ser Ser Ser Val Gly Tyr Met His
 1 5 10

<210> 183

10271-021-999 - Substitute Sequence Listing.txt

<211> 10
 <212> PRT
 <213> Homo sapiens

<400> 183
 Lys Ala Ser Leu Ser Val Gly Tyr Met His
 1 5 10

<210> 184
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 184
 Ser Ala Ser Leu Arg Val Gly Tyr Met His
 1 5 10

<210> 185
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 185
 Ser Ala Ser Leu Ser Val Gly Tyr Met His
 1 5 10

<210> 186
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 186
 Ser Ala Gln Ser Arg Val Gly Tyr Met His
 1 5 10

<210> 187
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 187
 Ser Ala Gln Leu Arg Val Gly Tyr Met His
 1 5 10

<210> 188
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 188
 Ser Ala Gln Ser Ser Val Gly Tyr Met His
 1 5 10

<210> 189
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 189
 Leu Pro Ser Leu Ser Val Gly Tyr Met His
 1 5 10

<210> 190

10271-021-999 - Substitute Sequence Listing.txt

<211> 10
 <212> PRT
 <213> Homo sapiens

 <400> 190
 Leu Pro Ser Ser Ser Val Gly Tyr Met His
 1 5 10

<210> 191
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 191
 Leu Pro Ser Leu Arg Val Gly Tyr Met His
 1 5 10

<210> 192
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 192
 Leu Cys Ser Ser Arg Val Gly Tyr Met His
 1 5 10

<210> 193
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 193
 Leu Cys Ser Leu Ser Val Gly Tyr Met His
 1 5 10

<210> 194
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 194
 Leu Cys Ser Ser Ser Val Gly Tyr Met His
 1 5 10

<210> 195
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 195
 Leu Cys Ser Leu Arg Val Gly Tyr Met His
 1 5 10

<210> 196
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 196
 Leu Pro Gln Ser Arg Val Gly Tyr Met His
 1 5 10

<210> 197

10271-021-999 - Substitute Sequence Listing.txt

<211> 10
 <212> PRT
 <213> Homo sapiens

<400> 197
 Leu Pro Gln Leu Ser Val Gly Tyr Met His
 1 5 10

<210> 198
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 198
 Leu Pro Gln Ser Ser Val Gly Tyr Met His
 1 5 10

<210> 199
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 199
 Leu Pro Gln Leu Arg Val Gly Tyr Met His
 1 5 10

<210> 200
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 200
 Leu Cys Gln Ser Arg Val Gly Tyr Met His
 1 5 10

<210> 201
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 201
 Leu Cys Gln Leu Ser Val Gly Tyr Met His
 1 5 10

<210> 202
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 202
 Leu Cys Gln Ser Ser Val Gly Tyr Met His
 1 5 10

<210> 203
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 203
 Leu Cys Gln Leu Arg Val Gly Tyr Met His
 1 5 10

<210> 204

10271-021-999 - Substitute Sequence Listing.txt

<211> 10
<212> PRT
<213> Homo sapiens

<400> 204
Ser Ala Gln Leu Ser Val Gly Tyr Met His
1 5 10

<210> 205
<211> 106
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> VL Domain

<400> 205
Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Gly Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
35 40 45
Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Gly Tyr Pro Phe Thr
85 90 95
Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105

<210> 206
<211> 120
<212> PRT
<213> Homo sapiens

<220>
<221> misc_feature
<223> VH Domain

<400> 206
Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15
Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30
Gly Met Ser Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
35 40 45
Trp Leu Ala Asp Ile Trp Trp Asp Asp Lys Lys Asp Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
65 70 75 80

10271-021-999 - Substitute Sequence Listing.txt

Val	Leu	Lys	Val	Thr	Asn	Met	Asp	Pro	Ala	Asp	Thr	Ala	Thr	Tyr	Tyr
				85					90					95	
Cys	Ala	Arg	Ser	Met	Ile	Thr	Asn	Trp	Tyr	Phe	Asp	Val	Trp	Gly	Gln
			100					105					110		
Gly	Thr	Thr	Val	Thr	Val	Ser	Ser								
		115					120								

APPENDIX C:

RETURN RECEIPT POSTCARD

STAMPED BY USPTO

ON NOVEMBER 21, 2006

NOV 6 2007

Express Mail No.: EQ 238 063 436 US

Date Mailed: November 21, 2006

Serial No.: 09/724,531

Filed: November 28, 2000

Inventor: Young *et al.*

For: METHODS OF ADMINISTERING/DOSING ANTI-RSV ANTIBODIES FOR PROPHYLAXIS AND TREATMENT

1. Request for Continued Examination (RCE) Transmittal (in duplicate);
2. Request for Continued Examination and Amendment;
3. Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.56 and § 1.97;
4. List of References Cited By Applicant;
5. Reference C24;
6. Transmittal of Substitute Sequence Listing;
7. Paper copy of Sequence Listing; and
8. CD of Sequence Listing in computer readable form.



File no.: 10271-021-999
CAM: 209073-999020

Sender: Anthony M. Insogna / Tamara M. Pertmer

6 2007

APPENDIX D:

NOTICE OF ALLOWABILITY

DATED JANUARY 26, 2007

NOV 6 2007

Notice of Allowability

Application No.

09/724,531

Examiner

Stacy B. Chen

Applicant(s)

YOUNG ET AL.

Art Unit

1648

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to 11/21/06.
2. ☒ The allowed claim(s) is/are 1, 3, 5, 179-184, 186, 187, 189, 192, 193, 195, 201, 204-212, 222-227, 231-233, 241, 242, 244, 245, 250, 280-299, 303, 305-324.
3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some* c) ☐ None of the:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).
- * Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
- (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
- 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
- (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
- Identifying Indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. ☒ Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date 11/21/06
4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material
5. ☐ Notice of Informal Patent Application (PTO-152)
6. ☐ Interview Summary (PTO-413),
Paper No./Mail Date _____.
7. ☐ Examiner's Amendment/Comment
8. ☒ Examiner's Statement of Reasons for Allowance
9. ☐ Other _____.

NOV 6 2007

Examiner's Statement of Reasons for Allowance:

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under Ex Parte Quayle, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on November 21, 2006 has been entered.

The amendments to the specification are corrections to the sequence listing and corresponding text in the disclosure that do not add new matter, as explained in the remarks filed on November 21, 2006. The amendments to the claims further clarify the claimed subject matter. Prior to the amendment filed November 21, 2006, Figures 2A and 2B did not have sequence identifiers. The addition of SEQ ID NO: 205 and 206 to the sequence listing corrects this deficiency and is not new matter. The addition of SEQ ID NO: 205 and 206 to the claims further defines the framework regions of the claimed antibodies. All pending claims are free of the prior art of record.

Stacy B. Chen 1/26/07

STACY B. CHEN
PRIMARY EXAMINER